<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079530</url>
  </required_header>
  <id_info>
    <org_study_id>K-877-CR-01</org_study_id>
    <nct_id>NCT04079530</nct_id>
  </id_info>
  <brief_title>A Clinical Pharmacology Study of K-877 Controlled Release Tablet</brief_title>
  <official_title>A Multicenter, Randomized, Active-controlled, Single-blind, 2-Period, 12-Sequence Crossover Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Pemafibrate in Patients With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Company, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare the efficacy, safety, and pharmacokinetics of K-877 controlled release
      tablets with a current normal K-877 tablet in dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 13, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: % change from baseline in fasting serum TG(mg/dL)</measure>
    <time_frame>4 week after administration in each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>% change from baseline in fasting HDL-C levels(mg/dL)</measure>
    <time_frame>4 week after administration in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change from baseline in fasting LDL-C levels(mg/dL)</measure>
    <time_frame>4 week after administration in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change from baseline in fasting non-HDL-C levels(mg/dL)</measure>
    <time_frame>4 week after administration in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change from baseline in fasting Total Cholesterol levels(mg/dL)</measure>
    <time_frame>4 week after administration in each period</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877 IR 0.2 mg/day</intervention_name>
    <description>K-877 IR 0.1 mg tablet</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_label>Treatment I</arm_group_label>
    <arm_group_label>Treatment J</arm_group_label>
    <other_name>Pemafibrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877 CR 0.4 mg/day</intervention_name>
    <description>K-877 CR 0.4 mg tablet</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_label>Treatment G</arm_group_label>
    <arm_group_label>Treatment H</arm_group_label>
    <arm_group_label>Treatment K</arm_group_label>
    <arm_group_label>Treatment L</arm_group_label>
    <other_name>Pemafibrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877 CR 0.8 mg/day</intervention_name>
    <description>Two K-877 CR 0.4 mg tablet</description>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_label>Treatment G</arm_group_label>
    <arm_group_label>Treatment H</arm_group_label>
    <arm_group_label>Treatment I</arm_group_label>
    <arm_group_label>Treatment J</arm_group_label>
    <arm_group_label>Treatment K</arm_group_label>
    <arm_group_label>Treatment L</arm_group_label>
    <other_name>Pemafibrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with dyslipidemia had to be age 20 years or older at written informed
             consent(ICF)

          2. Men and postmenopausal women.

          3. Patients who have received dietary or exercise guidance from 12 weeks prior to
             Screening.

          4. Patients who have clinical laboratory records with fasting serum TG ≥ 150 mg / dL (or
             ≥ 200 mg / dL if not fasting) within 6 months before written informed consent.

          5. Patients with a fasting serum TG ≥ 150 mg / dL at Screening.

        Exclusion Criteria:

          1. Patients with a fasting serum TG ≥ 500 mg / dL at Screening

          2. Patients who require administration of prohibited drugs during the clinical trial
             period after written informed consent

          3. Patients who have malabsorption or those who have had the history, or who have
             undergone other surgical procedures that may affect absorption (excluding appendectomy
             or hernia treatment etc)

          4. Patients with uncontrolled thyroid disease

          5. Patients with uncontrolled diabetes as defined by a HbA1c(NGSP) ≥ 8.0％ at Screening

          6. Persons with uncontrolled hypertension (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg)

          7. Patients with an AST or ALT three times the upper limit at Screening

          8. Patients with cirrhosis or those with biliary obstruction

          9. Patients with malignant tumor or those who are judged to have a high risk of
             recurrence

         10. Patients who have collected 400 mL or more of whole blood within 16 weeks, or 200 mL
             or more of whole blood within 4 weeks, or blood samples (plasma and platelet
             components) within 2 weeks before Screening

         11. Patients with a history of serious drug allergies (anaphylactic shock, etc.)

         12. Patients with a history of hypersensitivity to pemafibrate, patients who have stopped
             taking pemafibrate for reasons of insufficient efficacy or safety

         13. Patients who participate in other clinical trials at the time of written informed
             consent or who have received clinical trials other than placebo for less than 16 weeks

         14. Patients who have been determined inappropriate by the investigator or subinvestigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OPHAC Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>532-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

